ClinicalTrials.gg
Active, not recruitingNCT05345171Updated Sep 9, 2026

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

A Phase 3 interventional study of DTX301 and Placebo in OTC Deficiency, sponsored by Ultragenyx Pharmaceutical Inc. Active, not recruiting at 16 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Ultragenyx Pharmaceutical Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.

Enrollment
2nd of 12
37 · median 15
Started
2022
with 1 other
Phase 3
2 of 28
none open now
Primary completion
2027-09
later than 5 of 10 live
Registered
25th of 28
by date
Lead sponsor
6 of 28
Ultragenyx Pharmaceutical Inc

Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 3, reaches primary completion later than 5 of the 10 other live ones, and was the 25th registered.

Ornithine Carbamoyltransferase Deficiency Disease

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Open to participants now

6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.

Read the detailed description

This study is a Phase 3, randomized, double-blind, placebo-controlled study of DTX301 in patients with late-onset OTC deficiency 12 years of age and older.

Participants will be randomized 1:1 to DTX301 or placebo and followed closely for 36-64 weeks. Between Week 36 and Week 64, eligible participants will cross over and receive DTX301 if they had previously received placebo, and some who received DTX301 may receive placebo.

The planned study duration is up to 324 weeks. Upon completion of this study or early withdrawal, all participants who received DTX301 are invited to enroll in the Disease Monitoring Program (DMP) for follow-up for up to an additional 5 years.

03

Conditions studied

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed clinical diagnosis of late-onset OTC deficiency with historical documentation by enzymatic (ie, liver ), biochemical (ie, hyperammonemia in the presence of elevated plasma glutamine, low citrulline, and elevated spot urine orotic acid), or molecular testing (ie, OTC analysis)
  • Free from symptomatic hyperammonemia and has not required emergent active intervention for hyperammonemia within 4 weeks before screening/baseline
  • If on ongoing daily ammonia scavenger therapy, must be at stable daily dose(s) for ≥ 4 weeks prior to screening
  • If on a protein-restricted diet, must be on a stable total daily protein intake that does not vary more than 20% for ≥ 4 weeks prior to screening
  • From the time written through Visit 28, females of and fertile males must consent to use highly effective . If female, agree not to become pregnant. If male, agree not father a child or donate sperm

Key Exclusion Criteria:

  • Significant hepatic inflammation or cirrhosis
  • Estimated \< 60 mL/min/1.73 m2 at screening by the 2021 CKD-EPI creatinine-based formula (Inker et al., 2021) for patients ≥ 18 years of age or the Schwartz bedside formula (Schwartz and Work, 2009) for patients \< 18 years of age
  • Evidence of active virus (HBV) or virus (HCV) infection, documented by current use of antiviral therapy for HBV or HCV or by hepatitis B surface antigen (HBsAg) or HCV RNA positivity
  • Active infection (viral or bacterial)
  • Detectable pre-existing antibodies to the AAV8 capsid
  • Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results
  • Participation (current or previous) in another gene transfer study

Note: Additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    DTX301

    Participants receive single peripheral intravenous (IV) infusion of DTX301 in solution. Between Week 36 and Week 64, participants may receive single peripheral IV infusion of placebo.

    Genetic: DTX301 · Other: Placebo · Drug: Oral Corticosteroids · Drug: Placebo for oral corticosteroids · Drug: Sodium Acetate

  • Experimental
    Placebo, Then DTX301

    Participants receive single peripheral IV infusion of placebo. Between Week 36 and Week 64, participants receive single peripheral IV infusion of DTX301 in solution.

    Genetic: DTX301 · Other: Placebo · Drug: Oral Corticosteroids · Drug: Placebo for oral corticosteroids · Drug: Sodium Acetate

Interventions

  • GeneticDTX301

    non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector

    Also known as: avalotcagene ontaparvovec

  • OtherPlacebo

    normal saline infusion

  • DrugOral Corticosteroids

    Participants who receive DTX301 solution will receive oral corticosteroids.

    Also known as: Prednisolone

  • DrugPlacebo for oral corticosteroids

    Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind

  • A tracer for the Ureagenesis Rate Test (URT)

06

What researchers measure

Primary outcomes

  1. Plasma Ammonia as Measured by 24-Hour Ammonia (AUC0-24)

    Time frame: Week 36

  2. Complete Responder Rate at the Final Study Visit After DTX301 Exposure

    Time frame: Up to 64 Weeks Post DTX301 Infusion

Secondary outcomes

  1. Percentage of Complete Responders or Responders After DTX301 Exposure

    Time frame: Up to 64 Weeks Post DTX301 Infusion

  2. Annualized Event Rate of Hyperammonemic Crises (HACs) Pre-DTX301 Exposure vs Post-DTX301 Exposure

    Time frame: Pre-enrollment, Baseline, Up to 64 Weeks Post DTX301 Infusion

  3. Annualized Event Rate of Interim Clinical Events (ICEs) Pre-DTX301 Exposure vs Post-DTX301 Exposure

    Time frame: Pre-enrollment, Baseline, Up to 64 Weeks Post DTX301 Infusion

  4. Change from Baseline in Plasma Ammonia (AUC0-24)

    Time frame: Baseline, Up to Week 36

  5. Change in Plasma Ammonia (AUC0-24) After DTX301 Exposure

    Time frame: Up to 64 Weeks Post DTX301 Infusion

  6. Percentage of Participants Who Have Achieved Complete Management Response (CMR) or Management Response (MR) After DTX301 Exposure

    Time frame: Up to 64 Weeks Post DTX301 Infusion

  7. Change in Baseline Disease Management (Dietary Protein and Total Scavenger Medication Use) With Plasma Ammonia (AUC0-24)

    Time frame: Up to 64 Weeks Post DTX301 Infusion

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs, Related Serious TEAEs and Adverse Events of Special Interest (AESIs)

    Time frame: Up to Week 324

  9. Number of Participants With Anti-OTC Antibodies

    Time frame: Up to Week 324

  10. Long-Term Durability of Response

    Based Upon Number of Complete Responders or Responders That Have ≥ 2 Consecutive Visits as a Complete Responder or Responder and Do Not Return to a Lower Responder Status for \> 1 Consecutive Visit

    Time frame: Up to 64 Weeks Post DTX301 Infusion

  11. Change in Plasma Ammonia (AUC0-24) for Participants Who Have an Elevated Ammonia AUC0-24 at Baseline

    Time frame: Baseline, Up to 64 Weeks Post DTX301 Infusion

07

Study locations

16 sites
08

References and documents

Publications

  • Baruteau J, Brunetti-Pierri N, Gissen P. Liver-directed gene therapy for inherited metabolic diseases. J Inherit Metab Dis. 2024 Jan;47(1):9-21. doi: 10.1002/jimd.12709. Epub 2024 Jan 3. PubMed 38171926 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Sep 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Apr 25, 2022
StartActual
Oct 18, 2022
Primary completionEst.
Sep 2027
CompletionEst.
Mar 2031
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05345171
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Oct 18, 2022
Primary completion
Sep 2027 (estimated)
Completion
Mar 2031 (estimated)
Last update
Sep 9, 2026

Study contacts

Medical Director
study director · Ultragenyx Pharmaceutical Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Acetate

Start the discussion